Skip to main content

Table 2 Factors associated with withdrawal of peginterferon-α and ribavirin treatment in chronic hepatitis C patients

From: Regional disparities in interferon therapy for chronic hepatitis C in Japan: a nationwide retrospective cohort study

  Groups Univariate analysis Multivariate analysis
Factors Treatment accomplishment Treatment withdrawal Coefficient P-value B Odds ratio 95 % C.I.
Gender (Male/Female) 5824/5766 1184/1226 1.004 0.325 0.000 1.000 0.911–1.099
Age (≥65 years/<65 years) 3146/8423 930/1473 127.536 <0.001 −0.326 0.722 0.651–0.800
History of IFN treatment (naive/experienced) 8463/2928 1716/657 4.005 0.047 0.032 1.033 0.929–1.147
Genotype (1/2 + 3) 7326/4050 1953/397 311.818 <0.001 −1.007 0.365 0.324–0.412
Viral load (high/low) 10713/817 2248/141 4.327 0.038 −0.091 0.913 0.750–1.112
Pre-AST (U/L)a 43 [30–68] (n = 11511) 48 [34–73] (n = 2385)   <0.001 0.001 1.001 1.000–1.003
Pre-ALT (U/L)a 51 [31–87] (n = 11517) 52 [34–81] (n = 2384)   0.517    
Pre-PLT (x104/μL) 16.0 [13.0–20.0] 15.0 [12.0–19.0]   <0.001 0.001 1.001 0.990–1.013
(n = 11381) (n = 2349)
FIB-4 index 2.26 [1.48–3.42] 2.84 [1.84–4.28]   <0.001 −0.125 0.882 0.850–0.916
(n = 11349) (n = 2341)
Year of starting treatment – 2008 4624 804     Reference  
2009 2845 588 45.561 <0.001 −0.219 0.803 0.710–0.909
2010– 4119 1015    −0.496 0.609 0.545–0.680
Region Hokkaido/Tohoku 1404 318    −0.242 0.785 0.666–0.925
Kanto 793 124    0.180 1.197 0.958–1.497
Shin-etsu 528 114    0.020 1.020 0.802–1.297
Hokuriku 717 148    0.036 1.037 0.838–1.283
Tokai 814 145 20.418 0.009 0.231 1.260 1.019–1.558
Kinki 2385 544    −0.048 0.953 0.827–1.098
Chugoku 1890 380    0.006 1.006 0.864–1.172
Shikoku 476 115    −0.240 0.787 0.619–0.999
Kyushu 2589 522     Reference  
  1. The values of pre-AST, pre-ALT, pre-PLT, and FIB-4 index are shown as median [interquartile range]
  2. aSince pre-AST and pre-ALT were closely correlated (r = 0.872; P < 0.001), only pre-AST was included in multivariate analysis. Significant factors by multivariate analysis are shown in bold. The patients whose treatment performance could not be determined were excluded from this analysis (n = 55)
  3. ALT, Alanine aminotransferase; AST, Aspartate aminotransferase; C.I., Confidence interval; FIB-4, Fibrosis-4; IFN, Interferon; PLT, Platelets; SVR, Sustained virological response